What does CUSIP 05464T104 represent in this 13F holders report?

CUSIP 05464T104 is the security identifier for AXSM - Axsome Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held AXSM - Axsome Therapeutics, Inc. - Common Stock in Q2 2018?

34 institutional investors reported AXSM - Axsome Therapeutics, Inc. - Common Stock for Q2 2018. Use the holders table for investor-level position and value details.

Axsome Therapeutics, Inc. - Common Stock (AXSM)

CUSIP: 05464T104

Q2 2018 13F Holders as of 30 Jun 2018

Type / Class: Equity / Common Stock
Shares outstanding: 48,932,355
Total 13F shares: 4,098,087
Share change: -131,172
Total reported value: $13,112,972
Put/Call ratio: 288%
Price per share: $3.20
Number of holders: 34
Value change: -$296,661
Number of buys: 13
Number of sells: 11

Quarterly Holders Quick Answers

What is CUSIP 05464T104?
CUSIP 05464T104 identifies AXSM - Axsome Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2018
Previous quarter: Q1 2018

Recent filing periods for CUSIP 05464T104:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of AXSM - Axsome Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	2%	981,950	$2,406,000	—	31 Mar 2018	13F
ROYCE & ASSOCIATES LP	13F	Company	2%	956,000	$2,342,000	—	31 Mar 2018	13F
VANGUARD GROUP INC	13F	Company	1.1%	533,679	$1,307,000	—	31 Mar 2018	13F
STIFEL FINANCIAL CORP	13F	Company	0.83%	404,145	$990,000	—	31 Mar 2018	13F
Sio Capital Management, LLC	13F	Company	0.4%	193,290	$474,000	—	31 Mar 2018	13F
JPMORGAN CHASE & CO	13F	Company	0.37%	180,258	$442,000	—	31 Mar 2018	13F
Opus Point Partners Management, LLC	13F	Company	0.27%	133,500	$327,000	—	31 Mar 2018	13F
ALETHEA CAPITAL MANAGEMENT, LLC	13F	Company	0.24%	116,500	$285,000	—	31 Mar 2018	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.19%	94,205	$230,000	—	31 Mar 2018	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.18%	88,000	$216,000	—	31 Mar 2018	13F
SABBY MANAGEMENT, LLC	13F	Company	0.17%	81,159	$199,000	—	31 Mar 2018	13F
A.R.T. Advisors, LLC	13F	Company	0.12%	59,282	$145,000	—	31 Mar 2018	13F
BlackRock Finance, Inc.	13F	Company	0.1%	46,659	$115,000	—	31 Mar 2018	13F
Mariner, LLC	13F	Company	0.08%	41,525	$102,000	—	31 Mar 2018	13F
GROUP ONE TRADING LLC	13F	Company	0.08%	39,084	$96,000	—	31 Mar 2018	13F
BARCLAYS PLC	13F	Company	0.07%	35,600	$87,000	—	31 Mar 2018	13F
NORTHERN TRUST CORP	13F	Company	0.06%	30,453	$75,000	—	31 Mar 2018	13F
Walleye Trading LLC	13F	Company	0.06%	28,323	$69,000	—	31 Mar 2018	13F
Dynamic Technology Lab Private Ltd	13F	Company	0.05%	26,478	$65,000	—	31 Mar 2018	13F
TWO SIGMA SECURITIES, LLC	13F	Company	0.04%	20,126	$49,000	—	31 Mar 2018	13F
SHANDA ASSET MANAGEMENT HOLDINGS Ltd	13F	Company	0.04%	19,958	$49,000	—	31 Mar 2018	13F
BALDWIN WEALTH PARTNERS LLC/MA	13F	Company	0.04%	19,551	$48,000	—	31 Mar 2018	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.04%	17,318	$42,000	—	31 Mar 2018	13F
FORBES J M & CO LLP	13F	Company	0.03%	15,066	$37,000	—	31 Mar 2018	13F
PVG ASSET MANAGEMENT CORP	13F	Company	0.03%	14,240	$34,888	—	31 Mar 2018	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.03%	14,050	$34,000	—	31 Mar 2018	13F
MORGAN STANLEY	13F	Company	0.02%	9,010	$22,000	—	31 Mar 2018	13F
Intellectus Partners, LLC	13F	Company	0.02%	9,000	$22,000	—	31 Mar 2018	13F
Sandy Spring Bank	13F	Company	0.02%	8,755	$21,000	—	31 Mar 2018	13F
LADENBURG THALMANN FINANCIAL SERVICES INC.	13F	Company	0.01%	4,976	$12,000	—	31 Mar 2018	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.01%	4,200	$10,000	—	31 Mar 2018	13F
REILLY FINANCIAL ADVISORS, LLC	13F	Company	0.01%	4,000	$10,000	—	31 Mar 2018	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	2,697	$7,000	—	31 Mar 2018	13F
MEEDER ASSET MANAGEMENT INC	13F	Company	0%	1,195	$3,000	—	31 Mar 2018	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	3	$7	—	31 Mar 2018	13F

Institutional Holders of Axsome Therapeutics, Inc. - Common Stock (AXSM) as of Q2 2018

As of 30 Jun 2018, Axsome Therapeutics, Inc. - Common Stock (AXSM) was held by 34 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 4,098,087 shares. The largest 10 holders included FMR LLC, ROYCE & ASSOCIATES LP, VANGUARD GROUP INC, STIFEL FINANCIAL CORP, Alethea Capital Management, LLC, Sio Capital Management, LLC, Opus Point Partners Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT INC, and JPMORGAN CHASE & CO. This page lists 34 institutional shareholders reporting positions in this security for the Q2 2018 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2018 vs Q1 2018 Across Filers

Q1 2018 holders

Q2 2018 holders

Holder diff

-1

Investor	Q1 2018 Shares	Q2 2018 Shares	Share Diff	Share Chg %	Q1 2018 Value $	Q2 2018 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.